JP2005522433A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522433A5
JP2005522433A5 JP2003565527A JP2003565527A JP2005522433A5 JP 2005522433 A5 JP2005522433 A5 JP 2005522433A5 JP 2003565527 A JP2003565527 A JP 2003565527A JP 2003565527 A JP2003565527 A JP 2003565527A JP 2005522433 A5 JP2005522433 A5 JP 2005522433A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
nucleic acid
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003565527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522433A (ja
JP4613011B2 (ja
Filing date
Publication date
Priority claimed from FR0201584A external-priority patent/FR2835749B1/fr
Application filed filed Critical
Publication of JP2005522433A publication Critical patent/JP2005522433A/ja
Publication of JP2005522433A5 publication Critical patent/JP2005522433A5/ja
Application granted granted Critical
Publication of JP4613011B2 publication Critical patent/JP4613011B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003565527A 2002-02-08 2003-02-07 invivo遺伝子伝達を改善する医薬組成物 Expired - Lifetime JP4613011B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo
PCT/FR2003/000407 WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (3)

Publication Number Publication Date
JP2005522433A JP2005522433A (ja) 2005-07-28
JP2005522433A5 true JP2005522433A5 (cg-RX-API-DMAC7.html) 2006-03-16
JP4613011B2 JP4613011B2 (ja) 2011-01-12

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565527A Expired - Lifetime JP4613011B2 (ja) 2002-02-08 2003-02-07 invivo遺伝子伝達を改善する医薬組成物

Country Status (10)

Country Link
US (2) US7709452B2 (cg-RX-API-DMAC7.html)
EP (1) EP1471944B1 (cg-RX-API-DMAC7.html)
JP (1) JP4613011B2 (cg-RX-API-DMAC7.html)
AT (1) ATE326986T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003222896A1 (cg-RX-API-DMAC7.html)
CA (1) CA2473212C (cg-RX-API-DMAC7.html)
DE (1) DE60305443T2 (cg-RX-API-DMAC7.html)
ES (1) ES2265569T3 (cg-RX-API-DMAC7.html)
FR (1) FR2835749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066104A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
EP2331071A1 (en) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Novel multimodular assembly useful for intracellular delivery
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3125945B1 (en) * 2014-04-01 2019-09-11 Institut National de la Sante et de la Recherche Medicale (INSERM) Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
EP3225246A1 (en) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetic compound for improving efficiency of transfection
US20210000917A1 (en) 2018-03-05 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
CA3131824A1 (en) * 2019-03-11 2020-09-17 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
EP4704856A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
EP1038016A2 (en) * 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
WO2001005913A1 (en) 1999-07-16 2001-01-25 Reatech Phosphor addition in gasification
WO2001008709A1 (en) * 1999-07-28 2001-02-08 Valentis, Inc. Sonoporation of tumors
AU2001238485A1 (en) 2000-02-18 2001-08-27 The Immune Response Corporation Methods and compositions for gene delivery
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
DE60144338D1 (de) 2000-10-20 2011-05-12 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände

Similar Documents

Publication Publication Date Title
US20230287400A1 (en) Modified Guide RNAs
US20260035697A1 (en) Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing
Sharma et al. Versatility of peptide nucleic acids (PNA s): Role in chemical biology, drug discovery, and origins of life
JP6767976B2 (ja) 関節疾患の治療のためのメッセンジャーrna治療法
CA2919226C (en) Compositions and methods for delivering messenger rna
CN102177237B (zh) 用于贮存和稳定生物分子的基质和介质
US12150951B2 (en) Methods for promoting entry of an agent into a cell
CN117487776A (zh) Casz组合物和使用方法
FR2835749B1 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
KR20130051954A (ko) 베타-ENaC-관련 질환을 치료하기 위한 유기 조성물
US5132207A (en) Accelerated nucleic acid reassociation method
CN117396193A (zh) 用于递送rna的组合物和方法
TW202304474A (zh) 用於抑制晚期糖化終產物之受體表現之RNAi藥劑、其組合物及使用方法
WO2003101394A3 (en) Defensins: use as antiviral agents
Kırıcı et al. Purification of carbonic anhydrase from Capoeta umbla (Heckel, 1843) gills and toxicological effects of some metals on enzyme activity
JP2004501211A5 (cg-RX-API-DMAC7.html)
US20240384269A1 (en) Compositions containing nucleic acid nanoparticles and processes related to alteration of their physiochemical characteristics
JP3289912B2 (ja) ポリアミノ酸オリゴヌクレオチドキャリヤー
SG194626A1 (en) A method for manufacturing pegylated oligonucleotides
US20160136195A1 (en) Use of hgma-targeted phosphorothioate dna aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
JP2012509904A (ja) 核酸送達組成物および核酸送達法
JPH10158196A (ja) 核酸安定化用キャリアー
CN101530095A (zh) 污泥复合杀生剂
Poddar et al. ZIF polymorphs for nucleic acid delivery and targeted knockdown of gene expression in prostate cancer
WO2014059313A1 (en) Thermally stable enzymes, compositions thereof and methods of using same